Asahi Kasei (OTC:AHKSF) Stock, Quote.Headers.trade-ideas

Asahi Kasei Corp is a holding company that, through its subsidiaries, sells a variety of products and services. The firm is organized into four segments based on product or service. The chemicals and fibers segment, which generates the most revenue of any segment, sells ammonia-based products including plastic compounds and cellulose fiber. The homes and construction segment builds residential houses and sells thermal insulation. The electronics segment sells components for mobile phones including electronic compasses and lithium-ion battery separators. The healthcare segment sells medical devices including blood purification, blood transfusion, and bioprocess products. The majority of revenue comes from Japan.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAWW

ACER

ACRS

ADAP

ADRO

AHKSF

AKBA

AMCR

AMRX

ARCH

ASTC

ATHOF

ATRO

AVGR

AVNS

AWCMY

AWLCF

BCRX

BFIN

BIREF

BKQNY

BKRIF

BKRIY

BLCM

BRAC

BUDZ

CCXI

CDEV

CEIX

CHFS

CLAR

CMCLF

COHU

CPYYF

CRCM

CREAF

CTXS

CUYTY

Changyou Limited American Depositary Share

CYOU

DFIHY

DNAX

DNJR

DSFGY

EBCOF

ENDP

ENLC

ENTX

ERMAY

ESTE

ETRN

EVGN

EVLO

EXTN

EYEG

FOLGF

FRED

FRGI

GALXF

GLKIF

GPOR

GPRE

GSKY

HEPA

IGGGF

IMTL

INGVF

INND

IPSEY

ISUZY

JARLF

Stocks That Broke Yearly Lows Tuesday Morning

Asahi Kasei Corp

Asahi Kasei: Critical Care Should Improve In Margins And Revenues

Asahi Kasei offers to buy Calliditas Therapeutics for $1.1B

Shares of Swedish biotech Calliditas Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) shot up by nearly 70% in the premarket session today after Japanese conglomerate As...

M&A News: Asahi Kasei Offers to Acquire Calliditas in $1.1 Billion Deal

Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics

Travere gains on Novartis data for Filspari rival, Calliditas buyout

Suzhou MediLink partnered with Germany's BioNTech to use MediLink's TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties.

Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership

Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership

Asahi Kasei (JP:3407) has released an update. Asahi Kasei Corporation emphasizes its commitment to sustainable growth and enhancing corporate value...

Asahi Kasei Prioritizes Sustainable Growth and Diversity

Asahi Kasei (JP:3407) has released an update. Asahi Kasei Corporation has announced the absorption of its dormant, wholly owned subsidiary, Asahi F...

Asahi Kasei Streamlines Operations by Absorbing Subsidiary

Asahi Kasei (JP:3407) has released an update. Asahi Kasei Corp. has initiated a tender offer for Calliditas Therapeutics AB shares at SEK 208 each,...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Asahi Kasei

Asahi Kasei (AHKSF) Forecast

Asahi Kasei (OTC:AHKSF) Stock, Quote.Headers.trade-ideas